Pancreatic Cancer Research

Clinical trialNo phase (not a drug trial)Completed

Programs To Support You During Chemotherapy

GI 1549: PROGRAMS TO SUPPORT YOU DURING CHEMOTHERAPY (PRO-YOU) A Randomized Controlled Pilot Study of Yoga Compared to an Attention Control in Patients Receiving Chemotherapy

Outcome
Results posted; no analysis attached
Phase
No phase (not a drug trial)
Status
Completed
Study type
Interventional
Start
August 2016
Ended
January 2020
Enrollment
44 participants
Sites
2
Primary outcomes
Fatigue Assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS)
Sponsor type
Academic / other
Results posted
27 May 2021
Last update
14 October 2022

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Results

Primary endpoint
Results posted; no analysis attachedAs posted on ClinicalTrials.gov ↗, registry record of 14 October 2022
Primary outcome
Fatigue Assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS)Baseline: Group I (Yoga Skills Training): 53.1 (1.8), n = 23Baseline: Group II (Attention Control): 56.8 (1.9), n = 218 weeks: Group I (Yoga Skills Training): 53.0 (2.1), n = 238 weeks: Group II (Attention Control): 57.2 (2.2), n = 2110 weeks: Group I (Yoga Skills Training): 51.1 (2.2), n = 2310 weeks: Group II (Attention Control): 57.2 (2.4), n = 2114 weeks: Group I (Yoga Skills Training): 55.4 (2.2), n = 2314 weeks: Group II (Attention Control): 60.6 (2.3), n = 21Values: mean score on a scale, Standard ErrorTime frame: At baseline, 8 weeks, 10 weeks and 14 weeks after start of interventionNo analysis posted for this outcome (outcome 1)
Participants
Group I (Yoga Skills Training): 23 started, 23 completedGroup II (Attention Control): 21 started, 21 completed
Serious adverse events
Group I (Yoga Skills Training): 4 of 23Group II (Attention Control): 3 of 21Participants with at least one serious adverse event, of those at risk, as posted
19 secondary outcomes, the first 8 shown
Circadian Disruption (Daily)
Group I (Yoga Skills Training) 11.5 (2.8), n=23; Group II (Attention Control) 9.9 (3.4), n=21 [mean days, Standard Error]
Circadian Disruption (Daily)
Group I (Yoga Skills Training) 11.8 (2.3), n=21; Group II (Attention Control) 11.9 (2.3), n=19 [mean days, Standard Deviation]
Circadian Disruption (Recalled)
Baseline leisure score index (LSI): Group I (Yoga Skills Training) 19.6 (5.4), n=21; Group II (Attention Control) 19.9 (3.6), n=17 [mean score on a scale, Standard Error] (first of 4 rows)
Depressive Symptoms Assessed by PROMIS
Baseline: Group I (Yoga Skills Training) 49.9 (1.9), n=23; Group II (Attention Control) 51.4 (2.0), n=21 [mean score on a scale, Standard Error] (first of 4 rows)
Fatigue (Daily)
0-2 weeks: Group I (Yoga Skills Training) 49.18 (1.73), n=23; Group II (Attention Control) 53.27 (1.92), n=19 [mean score on a scale, Standard Error] (first of 2 rows)
Depressive Symptoms (Daily)
0-2 weeks: Group I (Yoga Skills Training) 43.96 (1.52), n=20; Group II (Attention Control) 45.49 (1.82), n=19 [mean score on a scale, Standard Error] (first of 2 rows)
Interleukin 6 [IL-6] Measured Using High-sensitivity Quantikine Immunoassay Kits
Group I (Yoga Skills Training) 5.6 (3.4 to 9.2), n=16; Group II (Attention Control) 4.6 (2.8 to 7.8), n=13 [mean pg/ml, 95% Confidence Interval]
Interleukin 6 [IL-6] Measured Using High-sensitivity Quantikine Immunoassay Kits
Group I (Yoga Skills Training) 0.58 (0.38 to 0.90), n=16; Group II (Attention Control) 0.58 (0.38 to 0.90), n=13 [mean pg/ml, 95% Confidence Interval]

Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This randomized pilot trial studies how well two supportive programs work for improving fatigue and depressive symptoms in patients with GI undergoing chemotherapy. Possible mediators such as psychological stress, circadian disruption, and inflammation, will also be explored.

Detailed description public domain (ClinicalTrials.gov)

PRIMARY OBJECTIVES: I. To conduct a pilot randomized controlled trial of the yoga skills training (YST) versus a caring attention control (AC) group among adults with colorectal cancer (CRC) receiving chemotherapy to determine preliminary efficacy for the primary outcome of fatigue, secondary outcome of depressive symptoms, and possible mediators (i.e., psychological stress, circadian disruption, inflammation) as assessed by standard measures. SECONDARY OBJECTIVES: I. To measure the impact of the YST versus the AC on daily assessments of fatigue, depressive symptoms, and proposed mediators in the same trial and explore relationships among daily and standard assessments. II. To qualitatively assess perceived efficacy of the YST and AC and acceptability of new methodology through semi-structured interviews in a subset of 20-40 participants. OUTLINE: Patients are randomized to 1 of 2 groups. GROUP I (YST): Patients participate in YST consisting of four 30 minute in-person yoga sessions at weeks 2, 4, 6, and 8 that instructs skills to enhance mindfulness and promote relaxation, through instruction of awareness, movement, breathing practices, and meditation. GROUP II (AC): Patients participate in four 30 minute in-person sessions of supportive conversation at weeks 2, 4, 6, and 8. After completion of study, patients are followed up at 4 weeks.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Fatigue Assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS) [At baseline, 8 weeks, 10 weeks and 14 weeks after start of intervention]. Mean, score on a scale (Standard Error). Baseline: Group I (Yoga Skills Training) (n=23): 53.1 (1.8); Group II (Attention Control) (n=21): 56.8 (1.9). 8 weeks: Group I (Yoga Skills Training) (n=23): 53.0 (2.1); Group II (Attention Control) (n=21): 57.2 (2.2). 10 weeks: Group I (Yoga Skills Training) (n=23): 51.1 (2.2); Group II (Attention Control) (n=21): 57.2 (2.4). 14 weeks: Group I (Yoga Skills Training) (n=23): 55.4 (2.2); Group II (Attention Control) (n=21): 60.6 (2.3).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Circadian Disruption (Daily) [At 0-2 weeks after start of intervention]. Mean, days (Standard Error). Group I (Yoga Skills Training) (n=23): 11.5 (2.8); Group II (Attention Control) (n=21): 9.9 (3.4).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Circadian Disruption (Daily) [At 8-10 weeks after start of intervention]. Mean, days (Standard Deviation). Group I (Yoga Skills Training) (n=21): 11.8 (2.3); Group II (Attention Control) (n=19): 11.9 (2.3).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Circadian Disruption (Recalled) [At baseline, 8 weeks, 10 weeks and 14 weeks after start of intervention]. Mean, score on a scale (Standard Error). Baseline leisure score index (LSI): Group I (Yoga Skills Training) (n=23): 19.6 (5.4); Group II (Attention Control) (n=21): 19.9 (3.6). 8 weeks leisure score index (LSI): Group I (Yoga Skills Training) (n=23): 24.1 (7.1); Group II (Attention Control) (n=21): 23.9 (6.2). 10 weeks leisure score index (LSI): Group I (Yoga Skills Training) (n=23): 19.8 (4.4); Group II (Attention Control) (n=21): 29.7 (12.0). 14 weeks leisure score index: Group I (Yoga Skills Training) (n=23): 24.1 (5.5); Group II (Attention Control) (n=21): 38.1 (12.8).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Depressive Symptoms Assessed by PROMIS [At baseline, 8 weeks, 10 weeks and 14 weeks after start of intervention]. Mean, score on a scale (Standard Error). Baseline: Group I (Yoga Skills Training) (n=23): 49.9 (1.9); Group II (Attention Control) (n=21): 51.4 (2.0). 8 weeks: Group I (Yoga Skills Training) (n=23): 47.4 (2.0); Group II (Attention Control) (n=21): 51.2 (2.1). 10 weeks: Group I (Yoga Skills Training) (n=23): 46.6 (2.3); Group II (Attention Control) (n=21): 50.5 (2.5). 14 weeks: Group I (Yoga Skills Training) (n=23): 49.1 (2.0); Group II (Attention Control) (n=21): 50.2 (2.1).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Fatigue (Daily) [At 0-2 weeks and 8-10 weeks after start of intervention]. Mean, score on a scale (Standard Error). 0-2 weeks: Group I (Yoga Skills Training) (n=23): 49.18 (1.73); Group II (Attention Control) (n=21): 53.27 (1.92). 8-10 weeks: Group I (Yoga Skills Training) (n=23): 51.00 (2.06); Group II (Attention Control) (n=21): 53.29 (2.38).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Depressive Symptoms (Daily) [At 0-2 weeks and 8-10 weeks after start of intervention]. Mean, score on a scale (Standard Error). 0-2 weeks: Group I (Yoga Skills Training) (n=23): 43.96 (1.52); Group II (Attention Control) (n=21): 45.49 (1.82). 8-10 weeks: Group I (Yoga Skills Training) (n=23): 44.38 (2.36); Group II (Attention Control) (n=21): 44.58 (1.89).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Interleukin 6 [IL-6] Measured Using High-sensitivity Quantikine Immunoassay Kits [At 2 weeks after start of intervention]. Mean, pg/ml (95% Confidence Interval). Group I (Yoga Skills Training) (n=16): 5.6 (3.4 to 9.2); Group II (Attention Control) (n=13): 4.6 (2.8 to 7.8).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Interleukin 6 [IL-6] Measured Using High-sensitivity Quantikine Immunoassay Kits [At 10 weeks after start of intervention]. Mean, pg/ml (95% Confidence Interval). Group I (Yoga Skills Training) (n=16): 0.58 (0.38 to 0.90); Group II (Attention Control) (n=13): 0.58 (0.38 to 0.90).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Soluble Tumor Necrosis Factor Receptor 1 [sTNF-R1] Measured Using High-sensitivity Quantikine Immunoassay Kits [At 2 weeks after start of intervention]. Mean, pg/ml (95% Confidence Interval). Group I (Yoga Skills Training) (n=16): 1633.8 (1222.1 to 2184.1); Group II (Attention Control) (n=13): 1727.5 (1281.6 to 2328.6).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Soluble Tumor Necrosis Factor Receptor 1 [sTNF-R1] Measured Using High-sensitivity Quantikine Immunoassay Kits [At 10 weeks after start of intervention]. Mean, pg/ml (95% Confidence Interval). Group I (Yoga Skills Training) (n=16): 0.87 (0.78 to 0.97); Group II (Attention Control) (n=13): 0.87 (0.78 to 0.97).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Tumor Necrosis Factor Alpha [TNF-alpha] Measured Using High-sensitivity Quantikine Immunoassay Kits [At 2 weeks after start of intervention]. Mean, pg/ml (95% Confidence Interval). Group I (Yoga Skills Training) (n=16): 1.6 (1.1 to 2.1); Group II (Attention Control) (n=13): 1.7 (1.2 to 2.3).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Tumor Necrosis Factor Alpha [TNF-alpha] Measured Using High-sensitivity Quantikine Immunoassay Kits [At 10 weeks after start of intervention]. Mean, pg/ml (95% Confidence Interval). Group I (Yoga Skills Training) (n=16): 1.01 (0.91 to 1.13); Group II (Attention Control) (n=13): 1.01 (0.91 to 1.13).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Psychological Stress Assessed by the Perceived Stress Scale (PSS) [At baseline, 8 weeks, 10 weeks and 14 weeks after start of intervention]. Mean, score on a scale (Standard Error). Baseline, mean: Group I (Yoga Skills Training) (n=22): 14.7 (1.5); Group II (Attention Control) (n=20): 16.5 (1.6). 8 weeks: Group I (Yoga Skills Training) (n=22): 11.4 (1.8); Group II (Attention Control) (n=20): 13.7 (1.9). 10 weeks: Group I (Yoga Skills Training) (n=22): 12.1 (1.8); Group II (Attention Control) (n=20): 12.3 (2.1). 14 weeks: Group I (Yoga Skills Training) (n=22): 12.5 (1.8); Group II (Attention Control) (n=20): 13.6 (1.9).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Psychological Stress Assessed by the PSS (Daily) [At 0-2 weeks and 8-10 weeks after start of intervention]. Mean, score on a scale (Standard Error). 0-2 weeks, mean: Group I (Yoga Skills Training) (n=20): 1.34 (0.36); Group II (Attention Control) (n=19): 1.58 (0.42). 8-10 weeks, mean: Group I (Yoga Skills Training) (n=20): 1.69 (0.55); Group II (Attention Control) (n=19): 1.78 (0.45).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Regulation of Psychological Stress Assessed by the Positive and Negative Affect Schedule-Expanded Form (Daily) [At 0-2 weeks and 8-10 weeks after start of intervention]. Mean, score on a scale (Standard Error). 0-2 weeks, mean: Group I (Yoga Skills Training) (n=20): 10.51 (0.55); Group II (Attention Control) (n=19): 9.59 (0.66). 8-10 weeks, mean: Group I (Yoga Skills Training) (n=20): 10.53 (0.74); Group II (Attention Control) (n=19): 10.36 (0.84).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Regulation of Psychological Stress Assessed Using the Cancer Behavior Inventory [At baseline, 8 weeks, 10 weeks and 14 weeks after start of intervention]. Mean, score on a scale (Standard Error). Baseline - Stress management: Group I (Yoga Skills Training) (n=23): 34.8 (1.4); Group II (Attention Control) (n=20): 34.2 (1.5). Baseline - Coping with treatment-related side effects: Group I (Yoga Skills Training) (n=23): 33.1 (1.8); Group II (Attention Control) (n=20): 30.6 (1.8). Baseline - Accepting cancer/maintaining positive attitude: Group I (Yoga Skills Training) (n=23): 37.8 (1.3); Group II (Attention Control) (n=20): 39.3 (0.9). Baseline - Affective regulation: Group I (Yoga Skills Training) (n=23): 28.2 (1.6); Group II (Attention Control) (n=20): 29.9 (1.6). 8 weeks - Stress management: Group I (Yoga Skills Training) (n=23): 38.1 (1.3); Group II (Attention Control) (n=20): 38.6 (1.9). 8 weeks - Coping with treatment-related side effects: Group I (Yoga Skills Training) (n=23): 37.1 (1.7); Group II (Attention Control) (n=20): 35.4 (2.1). 8 weeks - Accepting cancer/maintaining positive attitude: Group I (Yoga Skills Training) (n=23): 40.4 (1.2); Group II (Attention Control) (n=20): 38.9 (1.6). 8 weeks - Affective regulation: Group I (Yoga Skills Training) (n=23): 29.8 (2.1); Group II (Attention Control) (n=20): 31.8 (2.1). 10 weeks - Stress management: Group I (Yoga Skills Training) (n=23): 38.2 (1.1); Group II (Attention Control) (n=20): 38.5 (1.6). 10 weeks - Coping with treatment-related side effects: Group I (Yoga Skills Training) (n=23): 36.8 (1.6); Group II (Attention Control) (n=20): 37.5 (2.3). 10 weeks - Accepting cancer/maintaining positive attitude: Group I (Yoga Skills Training) (n=23): 40.6 (0.9); Group II (Attention Control) (n=20): 40.6 (1.6). 10 weeks - Affective regulation: Group I (Yoga Skills Training) (n=23): 30.1 (2.2); Group II (Attention Control) (n=20): 33.1 (2.3). 14 weeks - Stress management: Group I (Yoga Skills Training) (n=23): 39.2 (1.4); Group II (Attention Control) (n=20): 40.1 (1.1). 14 weeks - Coping with treatment-related side effects: Group I (Yoga Skills Training) (n=23): 37.0 (1.7); Group II (Attention Control) (n=20): 38.4 (1.5). 14 weeks - Accepting cancer/maintaining positive attitude: Group I (Yoga Skills Training) (n=23): 40.0 (1.2); Group II (Attention Control) (n=20): 41.1 (1.0). 14 weeks - Affective regulation: Group I (Yoga Skills Training) (n=23): 32.3 (2.1); Group II (Attention Control) (n=20): 34.0 (1.9).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Minutes of Home Practice Completed [Up 10 weeks after start of intervention]. Mean, minutes (Standard Error). Group I (Yoga Skills Training) (n=16): 11.2 (1.9); Group II (Attention Control) (n=14): 12.1 (6.3).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Percent of Planned In Person Intervention Sessions Attended [At baseline, 2 weeks, 8 weeks, 10 weeks and 14 weeks after start of intervention]. Number, total interventions actually completed. Group I (Yoga Skills Training) (n=23): 68; Group II (Attention Control) (n=21): 72.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Number of Participants With Successful Qualitative Data Collection [At 14 weeks after start of intervention]. Count Of Participants, Participants. Qualitative Interviews - Combined (n=43): 30.